Efficacy, reactogenicity, and safety of the adjuvanted recombinant zoster vaccine for the prevention of herpes zoster in Chinese adults ≥ 50 years: A randomized, placebo-controlled trial

• Auteurs principaux: Diana Alexandra Echeverria Proano (Auteur), Fengcai Zhu (Auteur), Xiaodong Sun (Auteur), Jesús Zoco (Auteur), Jyoti Soni (Auteur), Neeraj Parmar (Auteur), S. Omar Ali (Auteur)
• Format: Livre
• Publié: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Sujets: article
• Accès en ligne: Connect to this object online.

Phase III multi-country studies (ZOE-50/70) demonstrated that the adjuvanted recombinant zoster vaccine (RZV) was well tolerated and prevented herpes zoster (HZ) in healthy ≥ 50-year-olds, with a vaccine efficacy (VE) > 90% across age groups. These pivotal trials did not enroll participants from...